R. Aggarwal et al. / Journal of Fluorine Chemistry 130 (2009) 886–893
891
4. Experimental
(2 mmol) in the ethanol (30 ml), and the mixture was refluxed for
6 h. The reaction was monitored by tlc. The solvent was evaporated
and the tlc and 1H NMR of residue showed the formation of
products in the ratio given in Table 1. Column chromatography
separation using silica gel (100–200 mesh) with petroleum
ether:ethyl acetate (99:1) afforded 3, further elution of column
with petroleum ether:ethyl acetate (98:2) afforded 4, elution with
petroleum ether:ethyl acetate (96:4) afforded 6 and further elution
with petroleum ether:ethyl acetate (90:10) afforded 5.
TheIRspectraofthe compoundswererecordedonBuckScientific
IR M-500 spectrophotometer using KBr pellets (nmax in cmꢀ1), 1H
and 13C NMR spectra on a Bruker instrument at 300 and 75 MHz,
respectively; chemical shifts are expressed in
d-scale downfield
from TMS as an internal standard. 19F NMR spectra were run on DRX
300 and DPX 400 at 282 and 376 MHz, respectively, using
deuteriochloroform as a solvent. The internal standard for 19F
spectra was fluorotrichloromethane, setting the CFCl3 signal at d0.0.
Elemental analyses were performed at Sophisticated Analytical
Instrument Facility Central Drug Research Institute, Lucknow, India.
4.2.1. 5-Hydroxy-1-(3-methylquinoxalin-2-yl)-3-phenyl-5-
trifluoromethyl-D2-pyrazoline 3c
(43%) Mp. 144–146 8C; IR: (KBr, cmꢀ1) 3550
n(O–H), 1565
Fluorinated
b-diketones 2a–2c are available commercially and
n
(C55N); 1H NMR (CDCl3, 300 MHz)
d: 2.96 (s, 3H, CH3), 3.53 (dq,
other 2d–2f were prepared according to the literature procedure
[25,26]. 2-Hydrazino-3-methylquinoxaline 1 was also synthesized
according to the literature procedure [11].
1H, 2JH
¼ 18:6 Hz, 4JH
¼ 1:2 Hz, 4-HB), 3.69 (d, 1H,
ꢀCF
ꢀH
A
B
B
3
2JH
¼ 18:6 Hz, 4-HA), 7.38–7.40 (m, 3H, 300, 400, 500-H), 7.59–
ꢀH
A
B
7.75 (m, 5H, 50, 60, 70, 200, 600-H), 7.99–8.01 (m, 1H, 80-H), 8.80 (bs,
1H, 50-OH, exchangeable with D2O); MS (EI) m/z: 373 [M+1]+. Anal.
Calcd. for C19H15F3N4O: C, 61.29; H, 4.06; N, 15.05. Found: C, 61.26;
H, 4.02; N, 14.89.
4.1. General procedure for the preparation of 5-hydroxy-3-
substituted-1-(3-methylquinoxalin-2-yl)-5-trifluoromethyl-D2
-
pyrazolines 3a–3b, and 1-substituted-4-methyl-1,2,4-triazolo[4,3-
a]quinoxalines 5a–5b
4.2.2. 5-Hydroxy-1-(3-methylquinoxalin-2-yl)-3-(p-
methoxyphenyl)-5-trifluoromethyl-D2-pyrazoline 3d
An ethanolic solution (30 ml) of 2-hydrazino-3-methylqui-
noxaline 1 (0.35 g, 2 mmol) and trifluoromethyl-b-diketones 2a–
(31%) Mp. 94–96 8C; IR: (KBr, cmꢀ1) 3480
n
(O–H), 1509
n(C55N);
1H NMR (CDCl3, 300 MHz)
d: 3.00 (s, 3H, CH3), 3.58 (d, 1H,
2b (2 mmol) was refluxed for 6 h. The reaction was monitored by
tlc. On completion of reaction solvent was evaporated completely.
The tlc and 1H NMR of the reaction mixture showed the formation
of products in the ratio given in Table 1. Column chromatography
separation using silica gel (100–200 mesh) with petroleum
ether:ethyl acetate (99:1) afforded 3, and further elution with
petroleum ether:ethyl acetate (90:10) afforded 5.
2JH
¼ 18 Hz, 4-HB), 3.74 (d, 1H, 2JH
¼ 18 Hz, 4-HA), 3.88 (s,
ꢀH
ꢀH
A
B
A
B
3H, OCH3), 6.97 (d, 2H, 300, 500-H, J = 8.7 Hz), 7.66–7.69 (m, 4H, 60, 70,
200, 600-H), 7.78–7.81 (m, 1H, 50-H), 8.03–8.05 (m, 1H, 80-H), 8.60 (bs,
1H, 50-OH, exchangeable with D2O; MS (EI) m/z: 403 [M+1]+. Anal.
Calcd. for C20H17F3N4O2: C, 59.70; H, 4.26; N, 13.92. Found: C,
59.65; H, 4.21; N, 13.90.
4.1.1. 5-Hydroxy-3-methyl-1-(3-methylquinoxalin-2-yl)-5-
4.2.3. 5-Hydroxy-1-(3-methylquinoxalin-2-yl)-3-(p-chlorophenyl)-
trifluoromethyl-D2-pyrazoline 3a
5-trifluoromethyl-D2-pyrazoline 3e
(67%) Mp. 116–118 8C; IR: (KBr, cmꢀ1) 3448
n(O–H), 1501
(29%) Mp. 110–112 8C; IR: (KBr, cmꢀ1) 3406
n(O–H), 1511
(C55N); 1H NMR (CDCl3, 300 MHz)
d: 2.13 (s, 3H, CH3), 2.86 (s, 3H,
n
(C55N); 1H NMR (CDCl3, 300 MHz)
d: 2.96 (s, 3H, CH3), 3.57 (d, 1H,
n
CH3), 3.10 (dq, 1H, 2JH
¼ 18 Hz, 4JH
¼ 1:2 Hz, 4-HB), 3.38 (d,
ꢀCF
2JH
¼ 18 Hz, 4-HB), 3.74 (d, 1H, 2JH
¼ 18 Hz, 4-HA), 7.43 (d,
ꢀH
ꢀH
ꢀH
A
B
B
3
A
B
A
B
1H,2JH
¼ 18 Hz, 4-HA), 7.59–7.67 (m, 2H, 60, 70-H), 7.75–7.78(m,
2H, J = 8.7 Hz, 300, 500-H), 7.65–7.69 (m, 4H, 60, 70, 200, 600-H), 7.78–
7.81 (m, 1H, 50-H), 7.99–8.01 (m, 1H, 80-H), 8.81 (bs, 1H, 50-OH,
exchangeable with D2O); MS (EI) m/z: 407/409 [M+1]+. Anal. Calcd.
for C19H14ClF3N4O: C, 56.15; H, 3.47; N, 13.79. Found: C, 56.20; H,
3.35; N, 13.54.
ꢀH
A
B
1H, 50-H), 7.96–7.99 (m, 1H, 80-H), 8.9 (bs, 1H, 50-OH, exchangeable
with D2O); MS (EI) m/z: 311 [M+1]+. Anal. Calcd. for C14H13F3N4O: C,
54.19; H, 4.22; N, 18.06. Found: C, 54.53; H, 3.99; N, 19.05.
4.1.2. 5-Hydroxy-1-(3-methylquinoxalin-2-yl)-3,5-
bis(trifluoromethyl)-D2-pyrazoline 3b
4.2.4. 5-Hydroxy-1-(3-methylquinoxalin-2-yl)-3-(p-nitrophenyl)-5-
(75%) Mp. 84–86 8C; IR: (KBr, cmꢀ1) 3455
n
(O–H), 1505
n(C55N);
trifluoromethyl-D2-pyrazoline 3f
1H NMR (CDCl3, 300 MHz)
d: 2.76 (s, 3H, CH3), 3.31 (d, 1H,
(64%) Mp. 173–176 8C; IR: (KBr, cmꢀ1) 3466
n(O–H), 1551
n
(C55N); 1H NMR (CDCl3, 300 MHz)
d: 2.88 (s, 3H, CH3), 3.53 (dq,
2JH
¼ 18:6 Hz, 4-HB), 3.54 (d, 1H, 2JH
¼ 18:6 Hz, 4-HA),
ꢀH
ꢀH
A
B
A
B
7.61–7.64 (m, 2H, 60, 70-H), 7.72–7.75 (m, 1H, 50-H), 7.94–7.97 (m,
1H, 80-H), 8.6 (bs, 1H, 50-OH, exchangeable with D2O); MS (EI) m/z:
365 [M+1]+. Anal. Calcd. for C14H10F6N4O: C, 46.16; H, 2.77; N,
15.38. Found: C, 46.10; H, 2.85; N, 16.02.
1H, 2JH
¼ 18 Hz, 4JH
¼ 1:5 Hz, 4-HB), 3.71 (d, 1H,
ꢀCF
ꢀH
A
B
B
3
2JH
¼ 18 Hz, 4-HA), 7.57–7.64 (m, 2H, 60, 70-H), 7.72–7.75 (m,
ꢀH
A
B
1H, 50-H), 7.78 (d, 2H, J = 8.7 Hz, 200, 600-H), 7.92–7.95 (m, 1H, 80-H),
8.23 (d, 2H, J = 8.7 Hz, 300, 500-H), 8.67 (bs, 1H, 50-OH, exchangeable
with D2O); MS (EI) m/z: 418 [M+1]+. Anal. Calcd. for C19H14F3N5O3:
C, 54.54; H, 3.38; N, 16.78. Found: C, 54.49; H, 3.34; N, 16.85.
4.1.3. 1-Trifluoromethyl-4-methyl-1,2,4-triazolo[4,3-a]quinoxaline
5b
(19%) Mp. 190–92 8C; 1H NMR (CDCl3, 300 MHz)
d
: 3.10 (s, 3H,
CH3), 7.54–7.57 (m, 2H, 60, 70-H), 7.99–8.02 (m, 1H, 50-H), 8.06–8.09
(m, 1H, 80-H); 19F NMR (CDCl3, 282 MHz)
: ꢀ57.85 (s, CF3).
4.2.5. 1-(3-Methylquinoxalin-2-yl)-5-phenyl-3-
trifluoromethylpyrazole 4c
(30%) Mp. 122–124 8C; IR: (KBr, cmꢀ1) 3116, 1498; 1H NMR
d
(CDCl3, 300 MHz) d: 2.50 (s, 3H, CH3), 6.91 (s, 1H, 4-H), 7.26–7.30 (m,
5H, 200, 300, 400, 500, 600-H), 7.77–7.90 (m, 2H, 60, 70-H), 8.04–8.15 (m, 2H,
50, 80-H); MS (EI) m/z: 355 [M+1]+. Anal. Calcd. for C19H13F3N4: C,
64.77; H, 3.70; N, 15.81. Found: C, 64.36; H, 3.68; N, 15.47.
4.2. General procedure for the preparation of 5-hydroxy-3-aryl-1-(3-
methylquinoxalin-2-yl)-5-trifluoromethyl-D2-pyrazolines 3c–3f, 3-
trifluoromethyl-5-aryl-1-(3-methylquinoxalin-2-yl)pyrazoles 4c–4f,
3(5)-trifluoromethyl-5(3)-arylpyrazoles 6c–6f and 1-aryl-4-methyl-
1,2,4-triazolo[4,3-a]quinoxalines 5c–5f
4.2.6. 1-(3-Methylquinoxalin-2-yl)-5-(p-methoxyphenyl)-3-
trifluoromethylpyrazole 4d
(19%) Mp.118–1208C; IR: (KBr, cmꢀ1) 3120, 1501; 1H NMR
2-Hyrazino-3-methylquinoxaline
1
(0.35 g, 2 mmol) was
-diketone 2
slowly added to the corresponding trifluoromethyl-
b
(CDCl3, 300 MHz) d: 2.46 (s, 3H, CH3), 3.76 (s, 3H, OCH3), 6.78 (d,